Clevidipine is an ultra-short-acting intravenous calcium channel blocker used for the treatment of acute hypertension, particularly when oral antihypertensive therapy is ineffective or not feasible; it provides rapid onset of action with effects lasting up to 72 hours. It is specifically indicated for short-term blood pressure control during the perioperative period. Due to its rapid metabolism in the blood to inactive metabolites—without accumulation in the body—it is especially suitable for patients with advanced end-organ damage. Clevidipine exhibits high selectivity for vascular and myocardial tissues and demonstrates potent activity in reducing pulse rate, along with vasodilatory effects on both systemic and pulmonary vasculature.